What is Soleno Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Soleno Therapeutics's interest expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Soleno Therapeutics's Operating Income for the
three
months ended in Mar. 2024 was $ -23.07 Mil. Soleno Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
GuruFocus does not calculate Soleno Therapeutics's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Soleno Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soleno Therapeutics (NAS:SLNO) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Soleno Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-23.07 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $0.04 Mil.
Soleno Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| GuruFocus does not calculate Soleno Therapeutics's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Soleno Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
Soleno Therapeutics (Soleno Therapeutics) Business Description
Traded in Other Exchanges
Address
203 Redwood Shores Parkway, Suite 500, Redwood City, CA, USA, 94065
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome.
Executives
| Patricia C Hirano |
officer: See Remarks |
1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065 |
| Kristen Yen |
officer: See Remarks |
3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065 |
| Bhatnagar Anish |
director, officer: See Remarks |
3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065 |
| James H Mackaness |
officer: Chief Financial Officer |
1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
| Vivo Opportunity Fund Holdings, L.p. |
10 percent owner |
192 LYTTON AVENUE, PALO ALTO CA 94301 |
| Vivo Opportunity, Llc |
10 percent owner |
192 LYTTON AVENUE, PALO ALTO CA 94301 |
| Abingworth Bioventures Vii Lp |
10 percent owner |
PRINCES HOUSE, 38 JERMYN STREET, LONDON X0 SW1Y 6DN |
| Perceptive Life Sciences Master Fund Ltd |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Matthew Pauls |
director |
9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852 |
| Joseph Edelman |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Perceptive Advisors Llc |
10 percent owner |
51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Llp Abingworth |
10 percent owner |
38 JERMYN STREET, LONDON X0 SW1Y 6DN |
| Jack W Schuler |
10 percent owner |
100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045 |
| Carlyle Holdings I L.p. |
10 percent owner |
C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505 |
| Carlyle Holdings I Gp Sub L.l.c. |
10 percent owner |
C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505 |
Soleno Therapeutics (Soleno Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SLNO has been successfully added to your 